REG - Oxford BioDynamics - Amendment: Director/PDMR Shareholding

Oxford BiodynamicsAnnouncement

01/09/2023 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230901:nRSA1575La&default-theme=true

RNS Number : 1575L  Oxford BioDynamics PLC  01 September 2023

 

Oxford BioDynamics PLC

Amendment: Director/PDMR Dealings

1 September 2023 - Oxford, UK - Oxford BioDynamics PLC (AIM: OBD, "OBD" or the
"Company"), a biotechnology company developing precision medicine tests based
on the EpiSwitch® 3D genomics platform, announces that it has received notice
from Vulpes Investment Management Pte Ltd ("Vulpes") that on 26 January 2023
the Vulpes Testudo Fund purchased 443,673 Ordinary Shares of 1 pence each
("Ordinary Shares") at an average price of 14.75p rather than 343,673 Ordinary
Shares of 1 pence each ("Ordinary Shares") at an average price of 14.7p as
previously announced.

Therefore, Vulpes is currently interested in 28,448,756 shares in total.
Vulpes is controlled by Non-Executive Director, Stephen Diggle, who is
therefore deemed to be interested in a total of 28,448,756 shares,
representing approximately 14.06% of the Company's current issued share
capital.

The corrected notification below, made in accordance with the requirements of
UK Market Abuse Regulation, provides further details:

 1     Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                         Stephen Diggle
 2     Reason for the notification
 a)    Position/status                                              Director/PDMR
 b)    Initial notification /Amendment                              Amendment
 3     Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                         Oxford BioDynamics Plc
 b)    LEI                                                          2138005Y1TK258O5U928
 4     Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the financial instrument, type of instrument  Ordinary Shares of 1p par value each

        Identification code

                                                                    ISIN: GB00BD5H8572
 b)    Nature of the transaction                                    Purchase of Ordinary Shares
 c)    Price(s) and volume(s)

 Price(s)   Volume(s)
                                                                    £0.148      100,000
                                                                    £0.148      143,673
                                                                    £0.147      200,000
 d)    Aggregated information

       - Aggregated volume                                          443,673

       - Price                                                      £0.1475
 e)    Date of the transaction                                      26 January 2023
 f)    Place of the transaction                                     XLON

d)

 

Aggregated information

- Aggregated volume

- Price

 

443,673

£0.1475

e)

Date of the transaction

26 January 2023

f)

Place of the transaction

XLON

 

For more information:

 Oxford BioDynamics Plc                             Tel: +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital - Nominated Adviser                  Tel: +44 (0)20 7408 4090

 Stephane Auton / Iain Sexton

 Instinctif Partners - Financial PR                 Tel: +44 (0)20 7457 2020

 Melanie Toyne-Sewell / Rozi Morris / Adam Loudon   OxfordBioDynamics@instinctif.com

 

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
(Checkpoint Inhibitor Response Test) for cancer, a predictive immune response
profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022.

OBD's next commercial product will be the Prostate Screening EpiSwitch® (PSE)
blood test, due to be launched in Q4 2023.

In March 2021, the Company launched its first commercial prognostic test,
EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
(Covid Severity Test) and the first commercially available microarray kit for
high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community.

The Company has developed a proprietary 3D genomic biomarker platform,
EpiSwitch®, which can build molecular diagnostic classifiers for the
prediction of response to therapy, patient prognosis, disease diagnosis and
subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.

For more information, please visit the Company's website,
www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 10,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFLFBXKLXBBB